Radiation Boost Reduces Local Recurrence in DCIS Patients

Video

A study presented last month at ASTRO found that a boost of radiation therapy following lumpectomy in DCIS patients resulted in reduced rates of local recurrence.

A study presented last month at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting in Boston found that a boost of radiation therapy following lumpectomy in patients with ductal carcinoma in situ (DCIS) resulted in reduced rates of local recurrence.

The ipsilateral breast tumor recurrence–free survival in DCIS patients who received a radiation boost following whole breast radiation therapy experienced a reduction in local recurrence at 5 years (97.1% vs 96.3%), 10 years (94.1% vs 92.5%), and 15 years (91.6% vs 88%), with these differences achieving statistical significance (P = .013).

In this video, Meena S. Moran, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses the results.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content